Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 >= 50%: Results from EMPOWER-Lung 1 study.
Date
2021Author
Ozguroglu, Mustafa
Gogishvili, Miranda
Turk, Haci M.
Gumus, Mahmut
Chen, Chieh-I
Ivanescu, Cristina
Kilickap, Saadettin
Bondarenko, Igor
Cicin, Irfan
Harnett, James
Mastey, Vera
Naumann, Ulrike
Reaney, Matthew
Konidaris, Gerasimos
Sasane, Medha
Brady, Keri
Li, Siyu
Gullo, Giuseppe
Rietschel, Petra
Sezer, Ahmet
Metadata
Show full item recordCollections
- Makale [92796]